Sponsors (2)
The bill directs modest, recurring federal funding to accelerate midstage U.S.–Israel/Abraham Accords agricultural R&D and commercialization—boosting farmers, researchers, and economic ties—while increasing taxpayer costs and prioritizing partnered, near‑commercial projects that could crowd out purely domestic or basic research and limit open access to discoveries.
U.S. farmers and agribusinesses gain earlier access to validated midstage agricultural technologies and services, which can raise productivity, resilience, and incomes.
Researchers and U.S. agricultural institutions receive targeted federal funding and cooperative-program support (combined ~$20 million per year FY2026–2030) to accelerate U.S.–Israel and Abraham Accords joint R&D and scale midstage projects.
Strengthens U.S. international research and diplomatic ties by formalizing cooperation with Israel and Abraham Accords partners, supporting technology transfer and joint commercialization opportunities.
Taxpayers fund a recurring program (~$20 million per year in FY2026–2030), increasing federal outlays that could displace other priorities or require trade-offs in the budget.
Prioritizing projects with named foreign partners (Israel and Abraham Accords parties) may shift research focus and resources away from exclusively domestic priorities and could limit participation by other international collaborators.
Commercialization and patenting of jointly developed technologies can advantage private firms and may limit open access to discoveries for some farmers or researchers, reducing equitable diffusion of benefits.
Based on analysis of 4 sections of legislative text.
Authorizes FY2026–FY2030 funding and creates a BARD Fund accelerator to expand U.S.–Israel midstage cooperative agricultural research and partnerships.
Introduced February 13, 2026 by Eugene Simon Vindman · Last progress February 13, 2026
Creates and funds expanded U.S.–Israel cooperative agricultural research by amending the BARD Fund statute, naming Israel and Abraham Accords parties as explicit partners, and authorizing new midstage research support. It also establishes a BARD Fund “accelerator” program to fast-track and manage midstage projects, and authorizes recurring funding for both the Fund and the accelerator for fiscal years 2026–2030.